Amagasa Hidetoshi, Fukuda Akira, Yamada Azusa, Kakuta Ryuta, Kajiyama Daisuke, Kawaguchi Machiko, Shibuya Go, Maeda Shinsuke, Motoyama Kazuo, Ganno Hideaki, Imai Kenichirou, Ami Katsunori, Iida Satoshi, Andou Masayuki
Dept. of Surgery, Tokyo Metropolitan Health and Medical Treatment Corporation Toshima Hospital.
Gan To Kagaku Ryoho. 2018 Dec;45(13):2417-2419.
We report a case of unresectable pancreas cancer. A 70-year-old woman presented with worsening diabetes and serum CA19-9 elevation. A tumor with portal vein and supra-mesenteric vein invasion was observed by computed tomography. She was diagnosed with unresectable pancreas head cancer that was locally advanced. Chemotherapy was administered with gemcitabine and nab-paclitaxel for 19 courses, followed by gemcitabine alone for 4 courses. After the addition of 6 courses of chemotherapy, a 60%dose of chemotherapy was administered for 13 courses due to severe neutropenia. The patient died 32 months after the first visit. The 60% dose of gemcitabine and nab-paclitaxel also inhibited tumor growth. These findings suggest the effective and safe long-term use of gemcitabine and nab-paclitaxel.
